SCHEMBL6958322

SCHEMBL6958322

Cc1ccc(NC(=O)c2sccc2S(=O)(=O)Nc2onc(C)c2Cl)c(O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
EDNRA P25101 20/20 1.00
EDNRB P24530 8/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4631405 0.92 EDNRA (0.84) EDNRAEDNRB
SCHEMBL4632363 0.90 EDNRA (0.82) EDNRAEDNRB
SCHEMBL4631353 0.90 EDNRA (0.81) EDNRAEDNRB
SCHEMBL6152829 0.89 EDNRA (0.84) EDNRAEDNRB
SCHEMBL4631837 0.89 EDNRA (0.84) EDNRAEDNRB
SCHEMBL4632375 0.88 EDNRA (0.79) EDNRAEDNRB
SCHEMBL4631898 0.88 EDNRA (1.00) EDNRAEDNRB
SCHEMBL4631499 0.88 EDNRA (0.78) EDNRAEDNRB
SCHEMBL4632379 0.85 EDNRA (1.00) EDNRAEDNRB
SCHEMBL4631420 0.85 EDNRA (0.83) EDNRAEDNRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1130355-C Thienyl-, Furyl-, Pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin TEXAS BIOTECHNOLOGY CORP (US) 2003-12-10 CN claimed
EP-0819125-B1 THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN TEXAS BIOTECHNOLOGY CORP (US) 2003-06-18 EP claimed
CN-1184470-A Thienyl-, Furyl-, Pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin TEXAS BIOTECHNOLOGY CORP (US) 1998-06-10 CN claimed
CN-1636994-B Process of preparing alkali metal salys of hydrophobic sulfonamides and alkali metal salt produced thereby ENCYSIVE PHARMACEUTICALS INC 2010-05-12 CN disclosed
CN-100558724-C Adjust active sulphonamide of endothelium peptide and derivative thereof ANSEHIV PHARMACEUTICAL CORP (US) 2009-11-11 CN disclosed
CN-1215069-C Sulfonamides and derivatives thereof that modulate the activity of endothelin ENCYSIVE PHARMACEUTICALS INC (US) 2005-08-17 CN disclosed
CN-1636994-A Process of preparing alkali metal salys of hydrophobic sulfonamides and alkali metal salt produced thereby ENCYSIVE PHARMACEUTICALS INC (US) 2005-07-13 CN disclosed
CN-1179961-C Sulfonamides for the treatment of endothelin mediated diseases ��ɪϣ����ҩ��˾ 2004-12-15 CN disclosed
CN-1530366-A Sulphonic acid amide for regulating bast peptide activity and derivative thereof ��ɪϣ����ҩ��˾ 2004-09-22 CN disclosed
US-20010021714-A1 THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN ENCYSIVE PHARMACEUTICALS INC. 2001-09-13 US disclosed
CN-1253560-A Sulfonamides for the treatment of endothelin mediated diseases TEXA BIOTECHNOLOGY CORP (US) 2000-05-17 CN disclosed
CN-1231664-A Sulfonamides and derivatives thereof that modulate the activity of endothelin TEXAS BIOTECHNOLOGY CORP (US) 1999-10-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010021714-A1 THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN EDNRA, EDNRB, NPSR1 EDNRA 1/4885EDNRB 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.